One of the most meaningful milestones for start-ups and young companies is the establishment of a relationship with a larger pharma company, medical device/diagnostics firm, or provider network. You have spent a long time and countless hours going to partnering events, “kissing many frogs”, and dancing with partners that had two left feet! Now is the time to put YOUR best foot forward, now is the time to tell a compelling and cohesive story, now is the time to prioritize your terms and conditions, now is the time to solicit and nurture strategic collaboration, now is the time to prove to all stakeholders that you can maximize value for all parties.
Now is NOT the time to do this yourself! Hence, we have invited a few selected attorneys who are expert in these matters, in order to make certain you understand the framework, are able to navigate the pitfalls and pushbacks, and are well-versed in the intricacies and nuances of this important exercise. Please join us!
This webinar is brought to you jointly by SoPE and The George Washington University.
A retired ENT surgeon, Jeff has been involved in commercial ventures and is constantly on the look-out for new and innovative entrepreneurial opportunities. The exciting thing about life after the practice of medicine is that now he is able to draw upon the diversified fields of medicine, business, and organizational psychology, and implement novel solutions that have an immediate impact on the client’s bottom line. Currently, Jeff is the Chairman of the Board and Chief Medical Officer at BioFactura, Inc.
Brian Coblitz directs intellectual property protection and licensing for technologies developed at the George Washington University (GW). For over 9 years he managed the life sciences portfolio at GW, including the licensing of a drug for septic shock, which is on the market. He has helped to establish many life science startup companies based on GW technologies. Brian is also an angel investor and a member of the Life Science Angels. He is a registered U.S. Patent Agent. Prior to starting his career in technology commercialization at the NIH, Brian completed his postdoctoral studies on the sense of touch with Marty Chalfie at Columbia University. Brian’s Ph.D. and B.S. degrees came from the Johns Hopkins University School of Medicine and Tulane University, respectively.
Prashant Girinath, Ph.D. is a shareholder in Greenberg Traurig’s Intellectual Property and Technology Group. Prashant has designed and implemented IP strategy for companies through all strata, from startups to venture-backed and public companies. He helps clients with their legal needs and IP strategy from inception through public offerings and exits. Prashant works with clients on both the sell-side and the buy-side of M&A. Prashant has represented investors and companies in IP-related matters in financings in all stages from pre-seed to venture capital or private equity rounds and pre-IPO crossover rounds. Prashant has obtained thousands of patents for companies and aggressively developed complex IP portfolios with dominant patent positions that have helped facilitate significant partnering outcomes, especially in the life sciences. He has also represented many companies in licensing and partnering transactions.
Charles J. Andres, Ph.D. is a shareholder in Greenberg Traurig’s Intellectual Property and Technology Group. Charles is a registered patent attorney focused on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, transactional work, and related business matters. Charlie is experienced in drafting and prosecuting patent applications and developing high value patent portfolios in the U.S. and worldwide. He also has experience evaluating the claims of issued patents and has won cases before the Patent Trial and Appeal Board by brief and on oral argument, and has worked with foreign counsel to obtain favorable outcomes in European patent oppositions.
Errol Arkilic, PhD is a nationally recognized leader in technology transfer and entrepreneurship, is the Chief Innovation Officer at the University of California, Irvine, and Executive Director for UCI Beall Applied Innovation. Previously, Errol was the founding and lead program director for the National Science Foundation Innovation Corps program where he led the I-Corps effort from its inception.